9-Valent HPV Vaccine | Recombinant Prophylactic Vaccine for HPV Research

Description Contents hide 1 Product Description 1.1 Research Significance 2 Product Specifications 3 Mechanism of Action 3.1 1. Antigenic Presentation 3.2 2. Activation of Adaptive Immunity 3.3 3. Cross-Type Protection Mechanism 3.4 4. Long-Term Immune Memory 3.5 5. Comparative Immunogenicity Studies 4 Side Effects 5 Keywords 6 Shipping Guarantee 7 Trade Assurance 8 Payment Support 9 Disclaimer Product DescriptionThe 9-Valent Human Papillomavirus (HPV) Vaccine represents a major advancement in the field of immunological and virological research. It is designed to provide broad-spectrum coverage against nine key HPV genotypes—types 6, 11, 16, 18, 31, 33, 45, 52, and 58—that are associated with both low-risk and high-risk HPV infections.In laboratory research settings, this vaccine serves as a model system to explore the structural immunogenicity of L1 virus-like particles (VLPs), humoral immune response induction, and cross-neutralization across related HPV strains.The vaccine formulation consists of highly purified recombinant L1 capsid proteins self-assembled into non-infectious VLPs, produced using a yeast-based expression system. These VLPs closely mimic the native structure of HPV virions without containing viral DNA, ensuring biosafety for laboratory manipulation.Each HPV type in the 9-valent formulation contributes to the understanding of multivalent immune synergy and antigenic dominance patterns. Researchers utilize this preparation to examine B-cell activation, antibody avidity, and immune memory following multivalent antigen exposure.The 9-Valent HPV Vaccine provides a vital tool for:Studying vaccine-induced immunogenicity across multiple HPV genotypes.Characterizing neutralizing antibody epitopes and their role in viral entry inhibition.Assessing adjuvant mechanisms and their impact on the strength and duration of immune response.Investigating cross-type protection between phylogenetically related HPV strains.Modeling human immune responses using preclinical animal systems or in vitro assays.The 9-valent vaccine structure has also become a cornerstone for research into VLP vaccine technology, allowing scientists to compare recombinant antigen designs, purification methods, and adjuvant formulations that enhance immune recognition.Its application extends to molecular studies on capsid protein folding, assembly stability, and receptor-binding mechanisms critical to HPV infectivity.In preclinical immunology laboratories, this vaccine is commonly used to evaluate neutralizing antibody titers, cytokine responses, and germinal center B-cell dynamics. By comparing immune kinetics against monovalent and quadrivalent formulations, researchers gain insights into the optimization of next-generation, broad-spectrum HPV vaccine candidates.Research SignificanceThe 9-Valent HPV Vaccine facilitates research into:Multivalent vaccine development for viral pathogens.Immunodominance and antigen competition within complex formulations.Mucosal immunity mechanisms related to HPV infection sites.Long-term antibody persistence and memory B-cell activation.Adjuvant comparative studies, particularly alum- or AS04-based systems.The recombinant expression system provides consistent, high-yield VLP production with low endotoxin content, ensuring reproducibility in immunogenicity experiments. For laboratories focusing on vaccine design, structural virology, or comparative immunology, the 9-Valent HPV Vaccine serves as an essential control and reference model.Product SpecificationsItemDetailsProduct Name9-Valent Human Papillomavirus (HPV) VaccineSynonymsHPV9 Vaccine, Nonavalent HPV Vaccine, 9vHPVCAS Number—CompositionRecombinant L1 virus-like particles (VLPs) from HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58Molecular TypeRecombinant protein-based vaccineExpression SystemYeast (Saccharomyces cerevisiae)FormulationLiquid or lyophilized form, adjuvanted with aluminum hydroxyphosphate sulfatePurity≥99%AppearanceClear to slightly opalescent suspensionStorage2–8 °C, protected from lightApplicationsVaccine immunology, HPV antigenicity research, preclinical vaccine evaluationCategoryRecombinant VLP vaccineMechanistic FocusInduction of neutralizing antibodies against HPV L1 capsid antigensSupplier TypeLaboratory and preclinical research reagent providerIntended UseFor laboratory and preclinical research onlyMechanism of ActionThe 9-Valent HPV Vaccine works by mimicking the structure of the native HPV virion through its recombinant L1 capsid proteins, which self-assemble into virus-like particles (VLPs). These VLPs present the same conformational epitopes found on natural HPV, stimulating neutralizing antibody production without containing viral genetic material.1. Antigenic PresentationThe VLPs in the vaccine expose conformational epitopes that are recognized by the immune system as authentic viral structures. This induces a robust B-cell–mediated immune response, leading to the generation of high-affinity neutralizing antibodies.2. Activation of Adaptive ImmunityUpon administration in research models, the vaccine antigens are taken up by antigen-presenting cells (APCs), which process and present them to helper T-cells (CD4 ). This promotes cytokine release and stimulates B-cell maturation and antibody isotype switching.3. Cross-Type Protection MechanismAlthough each HPV type is represented by a distinct L1 VLP, the 9-valent formulation elicits cross-neutralizing antibodies due to partial epitope homology among related HPV genotypes, such as HPV16/31 and HPV18/45 clusters. This enables the exploration of broad-spectrum immunogenicity in laboratory assays.4. Long-Term Immune MemoryExperimental data indicate that the vaccine triggers durable immune memory characterized by sustained high antibody titers and persistent germinal center activity. These features make it a valuable model for studying immune longevity and booster response mechanisms.5. Comparative Immunogenicity StudiesResearchers often compare the 9-valent formulation with quadrivalent or bivalent HPV vaccines to evaluate antigenic competition, synergistic immune responses, and dose optimization. The inclusion of nine HPV L1 antigens allows detailed study of multivalent vaccine complexity.9-Valent HPV Vaccine for HPV ResearchSide EffectsFor laboratory and animal research contexts, the following considerations are noted:Minor local inflammatory reactions at the site of injection in model organisms.Mild fever or cytokine activation observed in immunized animals.No evidence of viral infection, as VLPs contain no DNA.Ensure all handling follows biosafety level 1 (BSL-1) standards.Avoid repeated freeze-thaw cycles to maintain VLP integrity.Keywords9-valent HPV vaccine, recombinant VLP, HPV L1 antigen, HPV immunogenicity, neutralizing antibody research, virus-like particle vaccine, HPV prevention research, multivalent vaccine development, high-purity HPV reagent, laboratory vaccine studyShipping GuaranteeAll shipments are handled using validated cold-chain logistics to preserve peptide and protein integrity. Each package is sealed in moisture-proof containers with temperature monitoring and shipped via express international couriers with full tracking.Trade AssuranceWe guarantee product authenticity, verified ≥99% purity, and analytical validation by HPLC and protein integrity assays. A Certificate of Analysis (CoA) is included with each batch. Replacement or refund applies if any deviation occurs.Payment SupportWe provide flexible international payment options: PayPal, major credit cards, telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are encrypted and verified to ensure data and fund security.DisclaimerAll products are intended for laboratory research use only. They are not vaccines for human or veterinary administration. No medical, diagnostic, or therapeutic claims are implied. Researchers must follow biosafety and institutional research regulations.